编码CD19/CD3双特异性T细胞参与者的麻疹病毒显示了增强的临床前抗BCP-ALL疗效,没有显著的毒性
Sabine Heinze1, Giovanna L Stadler1, Yonghui Zhang2
1Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, 89075 Ulm, Germany.
Molecular therapy. Oncology
|February 3, 2026
概括
一种新型瘤性麻疹病毒 (MV-Blina) 设计以向B细胞前体急性淋巴细胞白血病 (BCP-ALL) 显示出有前途. 这种疗法增强了抗白血病免疫力,毒性最小,为复发或耐火性BCP-ALL提供了希望.
科学领域:
- 瘤治疗性病毒疗法
- 免疫治疗是一种免疫疗法.
- 血液性恶性瘤 血液性恶性瘤
背景情况:
- 高风险的B细胞前体急性淋巴细胞白血病 (BCP-ALL) 具有复发和治疗耐药性的挑战.
- 对于BCP-ALL,急需新的治疗策略.
- 目前的治疗方法可能具有显著的全身毒性.
研究的目的:
- 开发和鉴定一种用于BCP-ALL治疗的重组性瘤性麻疹病毒 (MV-Blina).
- 设计MV-Blina以分泌针对CD19和CD3 (secBlina) 的双特异性T细胞诱导剂 (bsTE).
- 在临床前模型中评估MV-Blina的疗效和安全性.
主要方法:
- 开发MV-Blina,一种瘤性麻疹病毒分泌secBlina.
- 在体外评估MV-Blina的复制,细胞毒性和T细胞参与.
- 在体内研究使用患者衍生的异种移植和免疫功能低下的小鼠.
- 在体外和体内对神经毒性的评估.
主要成果:
- 与父母菌株相比,MV-Blina表现出增强的复制和细胞毒性.
- 分泌的secBlina有效地参与并激活T细胞,导致选择性白血病细胞死亡.
- MV-Blina在体内显示出显著的抗白血病作用和生存益处.
- 在神经元模型或小鼠中没有观察到显著的短期或长期毒性.
结论:
- MV-Blina是一种有前途的瘤性病毒疗法,用于BCP-ALL.
- 工程病毒有效地增强抗瘤免疫力,具有有利的安全性.
- 需要对MV-Blina对复发或耐火性BCP-ALL进行进一步的调查.
相关概念视频
Encoding
850
Information enters the brain through encoding, which is the input of information into the memory system. Once sensory information is received from the environment, the brain labels or codes it. The information is then organized with similar information and connected to existing concepts. Encoding occurs through automatic processing and effortful processing.
Automatic processing involves the encoding of details like time, space, frequency, and the meaning of words, usually done without conscious...
Automatic processing involves the encoding of details like time, space, frequency, and the meaning of words, usually done without conscious...
850
What are Viruses?
128.2K
Overview
128.2K
Self-Efficacy
227
Self-efficacy is the belief in one's capacity to organize and execute actions necessary to manage prospective situations. This belief significantly influences how individuals approach goals, tasks, and challenges across different domains of life.Psychological and Educational ImpactsIndividuals with strong self-efficacy are more resilient in the face of difficulties. They are more likely to adopt effective problem-solving strategies, persist through obstacles, and regulate emotions such as...
227
Preclinical Development: Overview
6.0K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.0K
Self-Evaluation: Self-Enhancement and Self-Verification
5.8K
Social psychologists have documented that feeling good about ourselves and maintaining positive self-esteem is a powerful motivator of human behavior (Tavris & Aronson, 2008). In the United States, members of the predominant culture typically think very highly of themselves and view themselves as good people who are above average on many desirable traits (Ehrlinger, Gilovich, & Ross, 2005). Often, our behavior, attitudes, and beliefs are affected when we experience a threat to our...
5.8K
Toxic Reactions: Overview
2.0K
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
2.0K


